Citations

Showing 10 of 108083 citations.

Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Schoen, Robert E. , Boardman, Lisa A. , Cruz‐Correa, Marcia , Bansal, Ajay , Kastenberg, David , Hur, Chin , Dzubinski, Lynda , Kaufman, Sharon F. , Rodriguez, Luz M. , Richmond, Ellen , Szabó, Éva , Salazar, Andres Μ. , McKolanis, John , Beatty, Pamela , Pai, Reetesh K. , Jacqueline, Camille M. , Bao, Riyue , Diergaarde, Brenda , Foster, Nathan R. , Zahrieh, David M. , Finn, Olivera J. , Umar, Asad , Szabo, Eva , Salazar, Andres , McKolanis, John , Beatty, Pamela , Pai, Reetesh K , Singhi, Aatur Dilip , Jacqueline, Camille M , Bao, Riyue , Diergaarde, Brenda , McMurray, Ryan P , Strand, Carrie A , Foster, Nathan R , Zahrieh, David , Limburg, Paul J , Finn, Olivera J , Richmond, Ellen S. , Boardman, Lisa , Schoen, Robert E , Cruz-Correa, Marcia , RODRIGUEZ, LUZ MARIA , McMurray, Ryan P. , Strand, Carrie , Limburg, Paul J.

Mayo Clinic

Clinical Cancer Research | March 9, 2023 | Volume: 29 | Issue: 9 | Pages: 1678-1688

10.1158/1078-0432.ccr-22-3168 | PMID 36892581 Get It

Abstract Purpose: To assess whether MUC1 peptide vaccine produces an immune response and prevents subsequent colon adenoma formation. Patients and Methods: Multicenter, double-blind, placebo-controlled randomized trial in individuals age 40 to 70 with diagnosis of an advanced adenoma ≤1 year from randomization. Vaccine was administered at 0, 2, and 10 weeks with a booster injection at week 53. Adenoma recurrence was assessed ≥1 year from randomization. The primary endpoint was vaccine immunogenicity at 12 weeks defined by anti-MUC1 ratio ≥2.0. Results: Fifty-three participants received the MUC1 vaccine and 50 placebo. Thirteen of 52 (25%) MUC1 vaccine recipients had a ≥2-fold increase in MUC1 IgG (range, 2.9–17.3) at week 12 versus 0/50 placebo recipients (one-sided Fisher exact P < 0.0001). Of 13 responders at week 12, 11 (84.6%) responded to a booster injection at week 52 with a ≥2-fold increase in MUC1 IgG measured at week 55. Recurrent adenoma was observed in 31 of 47 (66.0%) in the placebo group versus 27 of 48 (56.3%) in the MUC1 group [adjusted relative risk (aRR), 0.83; 95% confidence interval (CI), 0.60–1.14; P = 0.25]. Adenoma recurrence occurred in 3/11 (27.3%) immune responders at week 12 and week 55 (aRR, 0.41; 95% CI, 0.15–1.11; P = 0.08 compared with placebo). There was no difference in serious adverse events. Conclusions: An immune response was observed only in vaccine recipients. Adenoma recurrence was not different than placebo, but a 38% absolute reduction in adenoma recurrence compared with placebo was observed in participants who had an immune response at week 12 and with the booster injection.
More than meets the eye: the ocular toxicities accessory to anticancer therapies
Tailor, Prashant D. , Dalvin, Lauren A. , Fortes, Blake H , Tailor, Prashant D , Dalvin, Lauren A , Fortes, Blake H.

Mayo Clinic

Future Oncology | March 9, 2023 | Volume: 19 | Issue: 3 | Pages: 189-191

10.2217/fon-2022-0825 | PMID 36891943 Get It

Impaired gating of γ‐ and ε‐AChR respectively causes Escobar syndrome and fast‐channel myasthenia
Shen, Xin‐Ming , Nakata, Tomohiko, Mizuno, Seiji , Imoto, Issei, Selcen, Duygu , Engel, Andrew G. , Shen, Xin-Ming , Ohno, Kinji

Mayo Clinic

Annals of Clinical and Translational Neurology | March 9, 2023 | Volume: 10 | Issue: 5 | Pages: 732-743

10.1002/acn3.51756 | PMID 36891870 Get It

AbstractObjectiveTo dissect the kinetic defects of acetylcholine receptor (AChR) γ subunit variant in an incomplete form of the Escobar syndrome without pterygium and compare it with those of a variant of corresponding residue in the AChR ε subunit in a congenital myasthenic syndrome (CMS).MethodsWhole exome sequencing, α‐bungarotoxin binding assay, single channel patch‐clamp recordings, and maximum likelihood analysis of channel kinetics.ResultsWe identified compound heterozygous variants in AChR γ and ε subunits in three Escobar syndrome (1–3) and three CMS patients (4–6), respectively. Each Escobar syndrome patient carries γP121R along with γV221Afs*44 in patients 1 and 2, and γY63* in patient 3. Three CMS patients share εP121T along with εR20W, εG‐8R, and εY15H in patients 4, 5, and 6, respectively. Surface expressions of γP121R‐ and εP121T‐AChR were 80% and 138% of the corresponding wild‐type AChR, whereas εR20W, εG‐8R, and εY15H reduced receptor expression to 27%, 35%, and 30% of wild‐type εAChR, respectively. γV221Afs*44 and γY63* are null variants. Thus, γP121R and εP121T determine the phenotype. γP121R and εP121T shorten channel opening burst duration to 28% and 18% of corresponding wild‐type AChR by reducing the channel gating equilibrium constant 44‐ and 63‐fold, respectively.InterpretationSimilar impairment of channel gating efficiency of a corresponding P121 residue in the acetylcholine‐binding site of the AChR γ and ε subunits causes Escobar syndrome without pterygium and fast‐channel CMS, respectively, suggesting that therapy for the fast‐channel CMS will benefit Escobar syndrome.
Missorting of plasma miRNAs in aging and Alzheimer's disease
Čarná, Mária , Novotný, Jan , Dragišić, Neda, Slavík, Hanuš , Sheardová, Kateřina , Geda, Yonas E. , Laczó, Jan , Hort, Jakub , Mao, Zixu , Dammer, Eric B. , Novotny, Jan S , Vyhnalek, Martin , Hort, Jakub , Mao, Zixu , Rissman, Robert A. , Hajduch, Marian , Dammer, Eric B , Stokin, Gorazd , Geda, Yonas E , Vyhnálek, Martin , Stokin, Gorazd B.

Mayo Clinic

Journal of Neurochemistry | March 9, 2023 | Volume: 165 | Issue: 2 | Pages: 149-161

10.1111/jnc.15801 | PMID 36892419 Get It

Abstract The observation that aging is regulated by microRNAs (miRNA) and at the same time represents the greatest risk factor for Alzheimer's disease (AD), prompted us to examine the circulating miRNA network in AD beyond aging. We here show that plasma miRNAs in aging are downregulated and predicted to be preferentially targeted to the extracellular vesicle (EV) content. In AD, miRNAs are further downregulated, display altered proportions of motifs relevant to their loading into EVs and secretion propensity, and are forecast to be found exclusively in EVs. The circulating miRNA network in AD, therefore, reflects pathological exacerbation of the aging process whereby physiological suppression of AD pathology by miRNAs becomes insufficient. image
Effect of Cannabidiol Oil on Post-ureteroscopy Pain for Urinary Calculi: A Randomized, Double-blind, Placebo-controlled Trial
Narang, Gopal , Moore, Jonathan , Wymer, Kevin , Lim, Elisabeth S. , Humphreys, Mitchell R. , Stern, Karen , Lim, Elisabeth, Adeleye, Olufunmilola , Stern, Karen L , Chang, Yu‐Hui

Mayo Clinic

Journal of Urology | March 9, 2023 | Volume: 209 | Issue: 4 | Pages: 726-733

10.1097/ju.0000000000003139 | PMID 36891837 Get It

DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients
Cardona, Andrés F. , Chamorro, Diego F. , Ruíz-Patiño, Alejandro , Gómez, Diego F. , Muñoz, Álvaro , Ardila, Dora V., García-Robledo, Juan Esteban , Sussmann, Liliana, Mosquera, Andrés , Forero, Yency , Rojas, Leonardo , Hakim, Fernando, Jiménez, Enrique, Ramón, Juan Fernando, Cifuentes, Hernando, Pineda, Diego, Mejía, Juan Armando , Rodríguez, July, Archila, Pilar , Sotelo, Carolina , Chamorro Ortiz, Diego Fernando , Cardona, Andrés F , Garcia-Robledo, Juan Esteban , Sotelo-Rodríguez, Carolina , Rojas, Leonardo , Ordóñez‐Reyes, Camila , Pérez, Darwin Andrés Moreno , Arrieta, Óscar

Mayo Clinic

Neuro-Oncology Practice | March 9, 2023 | Volume: 10 | Issue: 4 | Pages: 381-390

10.1093/nop/npad014 | PMID 37457227 Get It

Abstract Background DICER1 alterations are associated with intracranial tumors in the pediatric population, including pineoblastoma, pituitary blastoma, and the recently described “primary DICER1-associated CNS sarcoma” (DCS). DCS is an extremely aggressive tumor with a distinct methylation signature and a high frequency of co-occurring mutations. However, little is known about its treatment approach and the genomic changes occurring after exposure to chemoradiotherapy. Methods We collected clinical, histological, and molecular data from eight young adults with DCS. Genomic analysis was performed by Next-generation Sequencing (NGS). Subsequently, an additional germline variants analysis was completed. In addition, an NGS analysis on post-progression tumor tissue or liquid biopsy was performed when available. Multiple clinicopathological characteristics, treatment variables, and survival outcomes were assessed. Results Median age was 20 years. Most lesions were supratentorial. Histology was classified as fusiform cell sarcomas (50%), undifferentiated (unclassified) sarcoma (37.5%), and chondrosarcoma (12.5%). Germline pathogenic DICER1 variants were present in two patients, 75% of cases had more than one somatic alteration in DICER1, and the most frequent commutation was TP53. Seven patients were treated with surgery, Ifosfamide, Cisplatin, and Etoposide (ICE) chemotherapy and radiotherapy. The objective response was 75%, and the median time to progression (TTP) was 14.5 months. At progression, the most common mutations were in KRAS and NF1. Overall survival was 30.8 months. Conclusions DCS is an aggressive tumor with limited therapeutic options that requires a comprehensive diagnostic approach, including molecular characterization. Most cases had mutations in TP53, NF1, and PTEN, and most alterations at progression were related to MAPK, RAS and PI3K signaling pathways.
Improved 2-Year Freedom from Arthroplasty in Patients with High-Risk SIFK Scores and Medial Knee Osteoarthritis Treated with an Implantable Shock Absorber versus Non-Operative Care
Pareek, Ayoosh , Parkes, Chad W. , Krych, Aaron J. , Krych, Aaron J , Gomoll, Andreas H.

Mayo Clinic

CARTILAGE | March 9, 2023 | Volume: 14 | Issue: 2 | Pages: 164-171

10.1177/19476035231154513 | PMID 37198901 Get It

Objective Subchondral insufficiency fracture of the knee (SIFK) is associated with high rates of osteoarthritis (OA) and arthroplasty. The implantable shock absorber (ISA) is an extra-capsular implant that unloads the medial knee compartment. This study compared the 2-year freedom from arthroplasty rates in subjects with medial knee OA and SIFK when treated with an ISA versus a matched cohort of patients treated non-surgically. Design This retrospective case-control study compared 2-year conversion rates to arthroplasty in SIFK score-, age-, and body mass index (BMI)–matched control subjects without prior surgical history with ISA-implanted subjects from an ongoing prospective study. Baseline and final radiographs, and MRIs were reviewed for evaluation of meniscus or ligament injuries, insufficiency fractures, and subchondral edema. Kaplan-Meier analysis assessed survival. Results Forty-two patients (21 Control: 21 ISA), mean age = 52.3 ± 8.7 years, BMI = 29.5 ± 3.9 kg/m 2 , 40% female were evaluated. Both ISA and Control arms had the same numbers of low ( n = 4), medium ( n = 11), and high-risk ( n = 6) SIFK scores. One- and 2-year freedom-from-arthroplasty rates were both 100% for ISA subjects, and 76% and 55%, respectively, for Controls ( P = 0.001 for cross-group comparison). Control knees with low, medium, and high-risk SIFK scores had respective 1- and 2-year survival rates of 100% and 100%, 90% and 68% ( P = 0.07 vs. ISA), and 33% and 0% ( P = 0.002 vs. ISA). Conclusions ISA intervention was strongly associated with avoidance of arthroplasty at a minimum 2 years, especially in patients with high-risk SIFK scores. SIFK severity scoring predicted relative risk of conversion to arthroplasty through at least 2 years in non-surgically treated subjects.
Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings
Hines, Alexander , Mohandesi, Nessa A., Lehman, Julia S. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Sartori‐Valinotti, Julio C. , Aghazadeh, Nessa , Hines, Alexander S , Cantwell, Hafsa M. , Sartori-Valinotti, Julio C., Lehman, Julia S , Aghazadeh Mohandesi, Nessa , Koster, Matthew J. , Alavi, Afsáneh , Warrington, Kenneth J. , Go, Ronald S.

Mayo Clinic

International Journal of Dermatology | March 9, 2023 | Volume: 62 | Issue: 7 | Pages: 938-945

10.1111/ijd.16635 | PMID 36890121 Get It

AbstractBackgroundVEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome is an autoinflammatory disease with frequent cutaneous manifestations.MethodsWe conducted a retrospective study of all patients with genetically confirmed VEXAS syndrome seen at our institution. Available clinical photographs and skin biopsy slides were reviewed.ResultsCutaneous manifestations developed in 22/25 (88%) patients with VEXAS syndrome. From this group, 10/22 (45%) developed skin involvement before or at the time of other clinical features of VEXAS. Twenty distinct dermatologic presentations of VEXAS from 14 patients were reviewed, and histopathologic patterns were classified as follows: neutrophilic urticarial dermatosis (n = 5, 25%), leukocytoclastic/urticarial vasculitis (n = 4, 20%), urticarial tissue reaction (n = 4, 20%), neutrophilic dermatosis (n = 3, 15%), neutrophilic panniculitis (n = 2, 10%), and nonspecific chronic septal panniculitis (n = 2, 10%). Common systemic findings included macrocytic anemia (96%), fever (88%), thrombocytopenia (76%), weight loss (76%), ocular inflammation (64%), pulmonary infiltrates (56%), deep venous thrombosis or pulmonary embolism (52%), and inflammatory arthritis (52%).ConclusionsCutaneous involvement is a common feature of VEXAS syndrome, and histopathologic findings exist on a spectrum of neutrophilic inflammatory dermatoses.
Safety and Performance of a Novel Implantable Sensor in the Inferior Vena Cava Under Acute and Chronic Intravascular Volume Modulation
Sheridan, William S., Wetterling, Friedrich , Fudim, Marat , Damman, Kevin , Gray, Alastair , Gaines, P.A. , Poloczek, Martin, Madden, Stephen F. , Buxó, Teresa , Gaul, Robert , Corcoran, Louise, Sweeney, Fiachra, Testani, Jeffrey M. , Borlaug, Barry A. , Tucker, James, Burkhoff, Daniel

Mayo Clinic

European Journal of Heart Failure | March 9, 2023 | Volume: 25 | Issue: 5 | Pages: 754-763

10.1002/ejhf.2822 | PMID 36891760 Get It

ABSTRACT Aims The management of congestion is one of the key treatment targets in heart failure. Assessing congestion is, however, difficult. The purpose of this study was to investigate the safety and dynamic response of a novel, passive, inferior vena cava (IVC) sensor in a chronic ovine model. Methods and results A total of 20 sheep divided into three groups were studied in acute and chronic in vivo settings. Group I and Group II included 14 sheep in total with 12 sheep receiving the sensor and two sheep receiving a control device (IVC filter). Group III included an additional six animals for studying responses to volume challenges via infusion of blood and saline solutions. Deployment was 100% successful with all devices implanted; performing as expected with no device-related complications and signals were received at all observations. At similar volume states no significant differences in IVC area normalized to absolute area range were measured (55 ± 17% on day 0 and 62 ± 12% on day 120, p = 0.51). Chronically, the sensors were completely integrated with a thin, reendothelialized neointima with no loss of sensitivity to infused volume. Normalized IVC area changed significantly from 25 ± 17% to 43 ± 11% (p = 0.007) with 300 ml infused. In contrast, right atrial pressure required 1200 ml of infused volume prior to a statistically significant change from 3.1 ± 2.6 mmHg to 7.5 ± 2.0 mmHg (p = 0.02). Conclusion In conclusion, IVC area can be measured remotely in real-time using a safe, accurate, wireless, and chronic implantable sensor promising to detect congestion with higher sensitivity than filling pressures.
T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection
Zhao, Zhen , Kumánovics, Attila , Love, Tanzy , Melanson, Stacy E.F. , Wu, Alan H.B. , Wiencek, Joesph R , Apple, Fred S. , Ondracek, Caitlin R. , Koch, David D., Christenson, Robert H. , Zhang, Yan Victoria, Wiencek, Joesph , Ondracek, Caitlin R , Meng, Qing H.

Mayo Clinic

Viruses | March 9, 2023 | Volume: 15 | Issue: 3 | Pages: 709

10.3390/v15030709 | PMID 36992418 Get It

Objectives: The objective of this prospective study was to investigate the role of adaptive immunity in response to SARS-CoV-2 vaccines. Design and Methods: A cohort of 677 vaccinated individuals participated in a comprehensive survey of their vaccination status and associated side effects, and donated blood to evaluate their adaptive immune responses by neutralizing antibody (NAb) and T cell responses. The cohort then completed a follow-up survey to investigate the occurrence of breakthrough infections. Results: NAb levels were the highest in participants vaccinated with Moderna, followed by Pfizer and Johnson & Johnson. NAb levels decreased with time after vaccination with Pfizer and Johnson & Johnson. T cell responses showed no significant difference among the different vaccines and remained stable up to 10 months after the study period for all vaccine types. In multivariate analyses, NAb responses (<95 U/mL) predicted breakthrough infection, whereas previous infection, the type of vaccine, and T cell responses did not. T cell responses to viral epitopes (<0.120 IU/mL) showed a significant association with the self-reported severity of COVID-19 disease. Conclusion: This study provides evidence that NAb responses to SARS-CoV-2 vaccination correlate with protection against infection, whereas the T cell memory responses may contribute to protection against severe disease but not against infection.